Inwentash buying at Avicanna (AVCN)

Inwentash buying at Avicanna (T:AVCN)

Sheldon Inwentash, a 10% Holder, acquired 1,959,000 Common Shares on a direct ownership basis at prices ranging from $0.272 to $0.290 between November 23rd, 2022 and November 25th, 2022. This represents a $538,068 investment into the company's shares and an account share holdings change of 74.1%.

Avicanna is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Avicanna Inc. is a Canada-based commercial-stage biopharmaceutical company. The Company is engaged in cannabinoid research, development, and evidence-based products for the global medical and pharmaceutical market segments. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products and Pharmaceutical Pipeline. Its Medical Cannabis & Wellness Products are marketed under the RHO Phyto brand and are a line of pharmaceutical-grade cannabis products containing varying ratios of cannabidiol (CBD) and tetrahydrocannabinol (THC). Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.